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Summary There are important interactions between prostatic tumours and bone. This study was designed to
examine whether prostatic tissue can express bone inductive factors, in particular, the Bone Morphogenetic
Proteins (BMPs). The polymerase chain reaction (PCR) has been used to screen for the expression of BMPs
one to six in the prostatic tissue of patients with benign prostatic hyperplasia (BPH), non-metastatic prostatic
adenocarcinoma and metastatic prostatic adenocarcinoma. BMPs were expressed in both benign and malig-
nant prostate tissue and in the prostate tumour cell lines, PC3 and DU145. BMPs were also expressed in
ocular melanoma tissue, a tissue which rarely metastasises to bone. BMP-6 expression was detected in the
prostate tissue of over 50% ofpatients with clinically defined metastatic prostate adenocarcinoma, but was not
detected in non-metastatic or benign prostate samples or in ocular melanoma tissue. These findings suggest
that the BMPs may play a role in the osteoinductive activity of prostate metastases and that the pattern of
expression of BMPs may be important in the pathogenesis of osteoblastic metastases associated with prostate
adenocarcinoma.
Prostate cancer is the third most common malignancy in men
in England and Wales (OPCS-Cancer Statistics, 1985). Of the
9,000 patients that present every year, approximately 50%
are already suffering from metastatic disease, one of the
major causes of their mortality (Whitmore, 1984). Current
investigative methods are still unable to predict with certainty
which patients are likely to develop metastases. This often
causes a dilemma for the clinician, and patients who might
go on to develop bony metastases may chose to remain
untreated, e.g. a simple observation and 'watch and wait'
policy is adopted. However, the availability of luteinizing
hormone releasing-hormone (LH-RH) analogues and anti-
oestrogens mean that treatment modalities are now available
for use in high-risk patients (Furr & Denis, 1988). There is,
therefore, a substantial need for criteria to define the metas-
tatic potential of individual prostate cancers.
Prostate carcinomas frequently metastasise to bone and
induce bone formation at specific sites, identifiable on X-ray
as marked radiodense or osteosclerotic foci (Charhon et al.,
1983). These so-called osteoblastic metastases result from an
imbalance in the rate of bone resorption and formation, with
osteoblasts depositing bone at sites independent of osteoclast
resorption. The mechanisms by which prostate tumour cells
induce new bone formation have yet to be determined. One
possibility is that the tumour cells secrete growth factors or
cytokines which act locally to stimulate the proliferation and
differentiation of osteoblasts. Human prostate cancer cells
have been found to produce a variety of known growth
factors including members of the fibroblast growth factor
(FGF) and transforming growth factor-P (TGF-P) families,
as well as transforming growth factor-x (TGF-ca) and epider-
mal growth factor (EGF) (Mydlo et al., 1988; Mori et al.,
1990; Thompson, 1990).
An important group of bone-inducing factors are the bone
morphogenetic proteins which have the capacity to induce
new bone formation when implanted ectopically into experi-
mental animals (Urist, 1965). Seven BMPs have so far been
identified and, with the exception of BMP-1, they are all
members of the TGF-P superfamily (Celeste et al., 1990;
Wozney et al., 1988; Wozney, 1989). To date there has been
no examination of BMP gene expression in prostatic tissue.
The aims of this study were 2-fold. Firstly, to establish
whether prostatic tissue and prostatic cell lines expressed the
genes for BMPs. Secondly, to examine the pattern of BMP
expression in patients with benign prostatic hyperplasia, and
metastatic and non-metastatic prostatic adenocarcinoma in
order to determine whether any differences in expression were
related to the tumorigenic and metastatic phenotype of the
prostatic cancer. The expression of BMPs one to six has been
determined by mRNA phenotyping (Brenner et al., 1989)
utilising specifically designed oligonucleotide primers selected
for non-homologous regions of the BMPs.
Materials and methods
Patients
Forty-one patients were studied. The study was approved by
the ethics committee and informed consent was obtained
from each patient prior to entering the study. Nineteen men
had histologically proven prostatic adenocarcinoma, 11 of
whom had skeletal metastases as shown by a positive tech-
netium 99-m bone scan. Twelve patients had known benign
prostatic hyperplasia (BPH) and 10 others had ocular mela-
nomas and were used as controls, since ocular melanomas
rarely metastasise to the bony skeleton and such metastases
are a very late phenomenon. None of the 10 ocular mela-
noma patients had bony metastases. Prostatic tissue samples
were obtained from transurethral resection specimens or by
transrectal needle core biopsy, and ocular melanoma samples
were obtained following enucleation. The nature of each
sample was confirmed by standard histological examination,
and graded using the Gleason scoring system (Gleason et al.,
1974). Samples were snap frozen in liquid nitrogen immedi-
ately after removal and stored at -70°C prior to RNA
extraction.
Cell lines
Two well characterised mycoplasma-free human prostate cell
lines, PC-3 (Kaighn et al., 1979) and DU145 (Stone et al.,
1978), were used. Cells were grown in Dulbecco's modified
Eagle's medium (DMEM) supplemented with 10% fetal calf
serum (FCS), glutamine, penicillin and streptomycin. The
cells were harvested by trypsin-EDTA treatment and passag-
ed at a ratio of 1:4 once a week.
Correspondence: H. Bentley.
Received 17 February 1992; and in revised form 17 July 1992.
Br. J. Cancer (1992), 66, 1159-1163 '." Macmillan Press Ltd., 19921160 H. BENTLEY et al.
Prior to RNA extraction, confluent monolayers of cells
were washed twice with PBS and stored at -70°C. For
experiments involving serum starvation, growth medium was
removed and confluent cell monolayers washed twice with
PBS. Then DMEM, supplemented with glutamine, penicillin
and streptomycin, and containing 0.1% bovine serum albu-
min (fraction V; Sigma) was added. Incubation was contin-
ued for 24 h before washing with PBS and storing at - 70°C.
RNA preparation
RNA was prepared from tissue samples or cell monolayers
by the acid guanidinium phenol chloroform (AGPC) method
(Chomczynski & Sacchi, 1987). Tissue samples were ground
in liquid nitrogen. Cells in monolayers or ground tissue were
then lysed in a denaturing solution containing guanidium
thiocyanate and extracted with phenol-chloroform. RNA
remaining in the aqueous phase was precipitated with isopro-
panol and then with ethanol at - 20°C. The final pellet of
RNA was dissolved in water, quantitated by reading the
optical density at 260 nm and stored at -20°C.
cDNA preparation
Total cellular RNA (2jig) was converted to cDNA by reverse
transcription using 600 units Molony Murine Leukemia
Virus (M-MLV) reverse transcriptase (Gibco BRL) in the
presence of 10 fig random hexamer primers and the four
dNTPs (0.125 mM each) in a buffer contianing 50 mM Tris
HCI, pH 8.3, 75 mM KCI, 10 mM dithiothreitol and 3 mM
MgCl2 in a total volume of 60flI. The reaction was incubated
at 37°C for 1 h.
Polymerase chain reaction
cDNA was amplified by PCR using two specific oligonucleo-
tide primers designed for specific gene sequences (Table I).
Since the BMPs show varying degrees of homology with each
other, primers were designed to unique regions specific for
the individual BMPs. Technical difficulties were enountered
with the designed BMP-7 primers. Two different sets of
primers for BMP-7 failed to produce a PCR product from a
range of cDNAs tested. As they could not be validated, they
were therefore excluded from this study. By using genomic
DNA instead of cDNA in the PCR, introns were shown to
be present for BMP-1, -3 and -6 but not for BMP-2, -4 and
-5 between the primers used. The reaction was carried out in
a total volume of 30 LI comprising of cDNA preparation
(1 LI), IX reaction buffer (NBL-supplied as lOX with Taq
DNA polymerase), dNTPs (200AM each), 1 unit Taq DNA
polymerase (NBL) and 10-20 pmol of each primer (quantity
was optimised for each primer pair). Amplification was car-
ried out in a Thermal Cycler (Hybaid). The cycle conditions
were as follows: denaturation at 93°C for 3 min followed by
34 cycles of denaturation at 93°C for 1 min, annealing at
60°C for 1.5 min and extension at 72°C for 30 s followed by 1
cycle of 93°C for min, 60°C for 1.5 min and 72°C for
10 min.
The reaction products were analysed by electrophoresis on
2% agarose gels (Gibco BRL) containing 0.1 jig ethidium
bromide/ml. For each sample PCR was repeated at least once
to avoid false positive or negative results. If the findings were
still inconclusive more cDNA was prepared from the original
RNA sample and PCR repeated twice more. For the two cell
lines the whole procedure starting from RNA extraction
from cells was carried out in duplicate. In all experiments,
primers from the beta-2 microglobulin gene were used as
controls for cDNA integrity and the presence ofcontaminant
genomic DNA. Negative controls (without cDNA) were
included for each primer set and no product was found (data
not shown).
Restriction analysis
The cDNA fragments produced by primer specific PCR were
designed to contain known restriction sites (Table I). A 7.5 JAI
aliquot of PCR product was further characterised by incuba-
tion with the appropriate restriction enzyme in a total
volume of 37.5 JlI and the cut fragments identified on 2%
agarose gels (data not shown).
PCR primers and products were considered to be validated
when a clean product of predicted cDNA size was observed
after amplification and was cleaved by predicted restriction
enzymes.
Results
PCR amplification of cDNA from the 41 patients and from
the two prostate cancer cell lines, PC3 and DU145 revealed
that BMP-1 to 6 were expressed in prostatic adenocarcinoma,
BMP-1 to 5 were expressed in benign prostatic hyperplasia
and ocular melanoma, BMP-1 and 4 were expressed in
DU145 cells and BMP-1, 2, 3, 4 and 6 were expressed in PC3
cells (Table II). Serum starvation was not found to alter the
pattern of BMP expression in the two cell lines. Examples of
PCR results are shown in Figure 1. Analysis of BMP expres-
sion in human tissue samples showed that BMP-6 was
expressed only in patients with prostatic adenocarcinoma
(32%). Table III shows the pattern of BMP expression in the
patients with prostatic adenocarcinoma after sub-dividing
them into two groups on the basis of a positive or negative
bone scan. With the exception of BMP-5, which was express-
ed in all prostatic samples, there was an increase in the
percentage of patients expressing each of the BMPs in the
bone scan positive compared with the bone scan negative
group. The proportion of patients with positive expression
for BMP-2 and BMP-3 appeared to be nearly twice as high
in patients with proven skeletal metastases. Most clearly,
BMP-6 was expressed in 55% of patients with positive bone
Table I PCR Primer Sequences
Product size Restriction Restriction
Primer Sequence (5' to 3' orientation) (bp) Site Products (bp)
BMP-1 (3') TCACAGCTGCACTTGTAGCTGCC 286 Haelll 221 +61
BMP-1 (5') TTGAGATTGAGCGCCACGACAGC
BMP-2 (3') GCTGTACTAGCGACACCCAC 671 TaqI 24 + 558 + 89
BMP-2 (5') TCATAAAACCTGCAACAGCCAACTCG
BMP-3 (3') TCAAATGAGTTCTTTGCCAGGTTATC 330 AccI 270 + 60
BMP-3 (5') CGCCAGGAGATACCTCAAGGTAGA
BMP-4 (3') GCTGAAGTCCACATAGAGCGAGTG 346 Alul 153 + 193
BMP-4 (5') ACTGGTCCACCACAATGTGACACG
BMP-5 (3') CCGAGATAACTGTATGCGACGAG 305 RsaI 97+208
BMP-5 (5') GGAGACAATCATGTTCACTCCAG
BMP-6 (3') CTGGGTAATAAGGCACTGGCATG 528 TaqI 134 + 394
BMP-6 (5') GTCGTAATCGCTCTACCCAGTCC
p2-MG (3') CTCCATGATGCTGCTTACATGTCTC 293 EcoRI 184 + 109
p2-MG (5') CAGGmTTACTCACGTCATCCAGCAG
p2-MG= Beta-2 microglobulin.BMP EXPRESSION IN PROSTATIC TISSUE 1161
Table II Bone morphogenetic protein expression in prostate tissue of patients with prostatic adenocar-
cinoma or benign prostatic hyperplasia, in ocular melanoma tissue, and in prostate cell lines
Number ofpositives (%)
Patients BMP-J BMP-2 BMP-3 BMP-4 BMP-S BMP-6
Prostatic adenocarcinoma n = 19 18 (95) 11 (58) 7 (37) 17 (89) 19 (100) 6 (32)
Benign prostatic hyperplasia n = 12 12 (100) 4 (33) 6 (50) 10 (83) 12 (100) 0 (0)
Ocular melanoma n = 10 10 (100) 5 (50) 6 (60) 10 (100) 9 (90) 0 (0)
Cell lines
DU145 (+ serum) + - - + - -
DU145 (-serum) + - - + -
PC3 (+ serum) + + + + - +
PC3 (- serum) + + + + - +
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Figure 1 Detection of BMP expression by the polymerase chain reaction in prostate tissue of patients with prostatic adenocar-
cinoma or benign prostatic hyperplasia, in ocular melanoma tissue, and in prostate cell lines. BMP expression in human prostatic
adenocarcinoma (metastatic) A, ocular melanoma B, PC3 cells cultured with serum C, or serum starved D, and DU145 cells
cultured with serum E, or without serum F. Lane 2, Kb ladder; Lanes 4 and 13, BMP1; Lanes 5 and 14, BMP2; Lanes 6 and 15,
BMP3; Lanes 7 and 16, BMP4; Lanes 8 and 17, BMP5; Lanes 9 and 18 BMP6; Lanes 10 and 19 P-2 microglobulin.
Table III Bone morphogenetic protein expression in prostate tissue ofprostatic adenocarcinoma patients
with positive and negative bone scans
Number ofpositives (%)
Patients BMP-J BMP-2 BMP-3 BMP-4 BMP-5 BMP-6
Bone scan positive n = 11 11 (100) 8 (73) 5 (45) 11 (100) 11 (100) 6 (55)
Bone scan negative n = 8 7 (88) 3 (38) 2 (25) 6 (75) 8 (100) 0 (0)
scans and not in any of the eight bone scan negative patients.
BMP expression did not appear to correlate with the grading
of the tumour, using the Gleason scoring system.
Discussion
There have been many attempts to isolate factors from pros-
tatic tissue that might stimulate osteoblast activity but the
nature of the tumour derived factor(s) responsible for the
osteogenic metastases has remained unclear (Jacobs et al.,
1979; Simpson et al., 1985; Maehama et al., 1986; Koutsi-
lieris et al., 1987; Story et al., 1987). In this paper we have
demonstrated that BMPs 1 to 6 are expressed in prostatic
adenocarcinoma, and this suggests that the BMPs may have
a role in the formation of skeletal metastases in prostate
cancer. BMP-6 appears to be selectively expressed in bone-
scan positive metastatic disease.
The recent availability of some of the BMPs in recombin-
ant form has enabled the effects of individual BMPs to be
studied in vivo. BMP-2 is the only member of the family so
far shown to induce bone formation when administered alone
(Wang et al., 1990), although BMP-3 and BMP-4 induce
endochondral bone formation in rats when implanted in a
carrier demineralised matrix (Luyten et al., 1989; Hammonds
et al., 1991). The increased incidence ofexpression ofBMP-2,
3 and 4 in prostatic tissue from patients with a positive bone
scan suggests that these may be candidates for the local
osteoblast stimulatory factor(s). However, widespread expres-
sion of the BMPs in prostate cell lines, benign prostatic
tissue, ocular melanomas and other human tissues as well
implies that they may have other activities in addition to
their bone morphogenetic properties. BMP-2 and Vgr-1 (the1162 H. BENTLEY et al.
murine equivalent of BMP-6) expression has been observed
in non-skeletal tissue in embryonic, newborn and adult mice
and it has been suggested that the co-ordinated expression of
these and other members of the TGF-P superfamily is requir-
ed to control the progression of specific cell types through
their differentiation pathways (Lyons et al., 1989), and that
BMP-2 plays multiple roles in morphogenesis and pattern
formation in the vertebrate embryo (Lyons et al., 1990).
Human BMP-6 has been identified in placenta and brain
cDNA libraries (Celeste et al., 1990). Because of the apparent
additional roles of the BMPs outside bone, it has been
suggested that they are renamed DVR (decapentaplegic-Vg-
related) proteins after the first two members of this family to
be identified (Lyons et al., 1991).
The relationship between the presence of mRNAs for
BMPs and the ability of that tissue to induce bone formation
remains unclear. It has been established that BMP-2 requires
post-translational processing, involving dimerisation and
cleavage, analogous to the processing of TGF-P, to produce
active BMP (Wang et al., 1990) and this may be the case for
the other BMPs. This process may be tissue dependent and
mediated by extracellular proteases. It may be that the level
of expression is important and is induced by certain as yet
unknown factors. Action of the BMPs may be dependent
upon the induction of specific receptors and specific, high-
affinity cell-surface binding proteins have been demonstrated
for BMP-4 (Paralkar et al., 1991).
The observation that there is a correlation between BMP-6
expression and bone metastases in prostate cancer warrants
further investigation. Although, from the data obtained it is
not possible to relate BMP expression to the ability of the
cancer cells to metastasise, it appears that BMP-6 expression
is correlated with the presence of skeletal metastases. The
nature of this relationship remains to be defined. In addition,
the relationship between the presence of mRNA for BMP-6
in prostatic tissue and its putative role require further work
to determine whether, like BMP-2, post-translational process-
ing (dimerisation and cleavage) is required for active BMP-6
to be produced by the cell. Analysis of other tumours which
produce osteoblastic metastases (breast, thyroid, lung) for
BMP-6 expression may provide additional evidence for a
relationship between BMP-6 expression and skeletal metas-
tases. Such studies may ultimately enable the identification of
sub-groups of patients with prostate cancer whose tumours
have invasive and metastatic potential, allowing treatment to
be directed at those most at risk of dying from this common
malignancy.
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